Mochida Pharmaceutical Co (FRA:MFY) FFO

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

FRA:MFY Mochida Pharmaceutical Co Ltd FRA:MFY
69 GF Score
Price €16.70
GF Value €19.64
! 4 Warning Signs
View Full Analysis

What is Mochida Pharmaceutical Co FFO?

FFO (Funds from operations) only applies to REITs.

FRA:MFY
69GF Score
Mochida Pharmaceutical Co Ltd FRA:MFY
FFO is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Is Mochida Pharmaceutical Co (FRA:MFY) Overvalued in 2026?

Based on GuruFocus' analysis, Mochida Pharmaceutical Co stock appears to be undervalued. The current stock price of €16.70 is trading 15% below its estimated GF Value™ of €19.64.

Key valuation signals for FRA:MFY:

  • FFO:
  • GF Value™: €19.64 vs. price of €16.70 (15% below fair value)
  • GF Score™: 69/100 with 4 warning signs

No single metric tells the full story. See the FRA:MFY stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


Mochida Pharmaceutical Co Business Description

Other Exchanges 4534:Japan
Address 1-1 Ichigayahonmuracho, Shinjuku-ku, Tokyo, JPN, 162-0845
Mochida Pharmaceutical Co Ltd is a major drug manufacturing company that operates in the field of medical care through its pharmaceuticals, healthcare products, and medical equipment businesses. The company's pharmaceuticals business aims to develop and market a broad spectrum of innovative new drugs. One of Mochida's main objectives is to maximize the business performance of its drugs after they are developed and released. The company also creates skin care products for the general public, and these are supplied through pharmacies, drugstores, and mail-order sales.
69GF Score

Get the complete analysis for FRA:MFY

FFO is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€16.70
Price
€19.64
GF Value